Clinical Trial Update: HSPPC-96 Vaccine With Temozolomide in Patients With Newly Diagnosed GBM [Phase 2]

View source ↗

Summary

Phase 2 trial update for HSPPC-96 vaccine with temozolomide in newly diagnosed glioblastoma multiforme patients; study completed with posted results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Glioblastoma

Drugs mentioned

• HSPPC-96 vaccine (HSPPC-96)
• Temozolomide (Temozolomide)

Snippet

Sponsor: University of California, San Francisco | Conditions: Brain and Central Nervous System Tumors | Phase 2 | Status: COMPLETED | Results posted: 2021-03-24